Physician profile
Barry Hendrix
NPI 1558440180
$532.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $90.84 · 2021: $61.61 · 2023: $200 · 2024: $22.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.47 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $126.36 | 2023 | Fisher & Paykel Healthcare |
| Astrazeneca Pharmaceuticals LP | $56.36 | 2019-2024 | Airsupra |
| Abbvie INC. | $52.62 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.98 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.19 | 2019 | |
| Glaxosmithkline, LLC. | $14.76 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.83 | 2021 | |
| Amgen INC. | $12.79 | 2019 | |
| Lilly USA, LLC | $12.65 | 2021 | |
| Merck Sharp & Dohme LLC | $12.52 | 2020 | |
| Allergan, INC. | $11.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.